Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1993-3-10
pubmed:abstractText
The relationship between structural specificity of the main stages of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) action and the display of parkinsonogenic properties among homologous structures in a number of 4-tolyl derivatives of MPTP has been studied. All the compounds are better substrates for monoamine oxidase (MAO) than MPTP. MAO is inactivated during the reaction according to a mechanism of irreversible inhibition by 2,3-dihydropyridinium metabolite. All the tolyl derivatives are stronger inhibitors of MAO than 1-methyl-2,3-dihydropyridinium (MPDP). A significant contribution of enzyme inhibition to the catalytic conversion of the substrate leads to the fact that substrates having equal (para isomer) or even higher (meta isomer) values of catalytic parameters are oxidized by MAO to a lesser extent than MPTP. It has been found that all 4-arylpyridiniums (final products of MATP bioconversion) competitively and reversibly inhibit [14C]dopamine (DA) uptake in mouse brain synaptosomes. Affinity toward DA transporter characterized by KI (microM) is 0.37 +/- 0.04, 0.7 +/- 0.1, 2.0 +/- 0.15, 2.0 +/- 0.35 for MPP, and its o-, m-, and p-tolyl derivatives, respectively. Joint calculation of specificity factors for the processes discussed define the following rank order for the bio-delivery of MATP's metabolic produces into DA nerve terminals: o-tolyl > MPTP >> m-tolyl > p-tolyl. The regularity revealed is in good agreement with the observed relative potency of these compounds to cause dopaminergic neurodegeneration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1044-7393
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
189-200
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:1362875-1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, pubmed-meshheading:1362875-Animals, pubmed-meshheading:1362875-Brain Chemistry, pubmed-meshheading:1362875-Dopamine, pubmed-meshheading:1362875-Dopamine Agents, pubmed-meshheading:1362875-Guinea Pigs, pubmed-meshheading:1362875-Kinetics, pubmed-meshheading:1362875-MPTP Poisoning, pubmed-meshheading:1362875-Mice, pubmed-meshheading:1362875-Mice, Inbred C57BL, pubmed-meshheading:1362875-Mitochondria, Liver, pubmed-meshheading:1362875-Monoamine Oxidase, pubmed-meshheading:1362875-Nerve Degeneration, pubmed-meshheading:1362875-Neurons, pubmed-meshheading:1362875-Norepinephrine, pubmed-meshheading:1362875-Parkinson Disease, Secondary, pubmed-meshheading:1362875-Structure-Activity Relationship, pubmed-meshheading:1362875-Synaptosomes
pubmed:year
1992
pubmed:articleTitle
Molecular basis of discrepancies in neurotoxic properties among 1-methyl-4-aryl-1,2,3,6-tetrahydropyridines.
pubmed:affiliation
Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernoglovka, Moscow Region.
pubmed:publicationType
Journal Article, In Vitro